BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. is listed today as Briacell Therapeutics Corp. : market value, financials and filings are on its company page.
Funding rounds 1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
Funding rounds of BriaCell Therapeutics Corp. Month Raised Raise Size Investors Sold Filing Jun 2021 $27 M No. 1 $10 to $50 million 12
BriaCell Therapeutics Corp.: Raise no. 1, Jun 2021 × Investors in this round 12 investors had bought by the notice of Jun 15, 2021: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $27 M of $27 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,175,680
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in British Columbia, Canada People named in the notice Gadi Levin · Executive Officer Jamieson Bondarenko · Executive Officer, Director William Williams · Executive Officer, Director Martin Schmieg · Director Rebecca Taub · Director Vaughn Embro-Pantalony · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round ThinkEquity, a division of Fordham Financial Management, Inc. (CRD 20996) · New York, New York Sold in CA, NJ, NV, NY Remarks in the notice On fees: “The above amount reflects a cash fee equal to 8% of gross proceeds, including exercise price of the pre-funded warrants. The Placement Agent also received a number of warrants equal to 5% of the Units sold in this offering.”On the amounts: “Offering consists of 4,370,343 common shares at a purchase price of USD 5.26; 800,000 pre-funded warrants at a purchase price of USD 5.25 with an exercise price of USD 0.01 per share and 5,170,343 warrants with an exercise price of USD 6.19 per share”Signed by William V. Williams, Chief Executive Officer. Newest notice filed Jun 15, 2021. Read the notice at the SEC .
equity, options SEC Nov 2014 $6 M Issued in a merger or acquisition $2 to $10 million 7
BriaCell Therapeutics Corp.: Private sale, Nov 2014 × Investors in this round 7 investors had bought by the notice of Dec 12, 2014: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: 833,333 Warrants are exercisable to purchase one additional common share at price of $0.25 for first 12 months after closing and $0.35 during the subsequent 24 months. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue not stated
Sales commissions none
Finders' fees $1
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in British Columbia, Canada People named in the notice Charles Wiseman · Executive Officer, Director Rahoul A. Sharan · Executive Officer, Director Isaac A. Maresky · Director Saeid Babei · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “1 PowerOne Capital Markets Limited of Toronto, Ontario, received 200,000 shares as a finder's fee for introducing the Issuer to BriaCell Therapeutics Corp.”On the amounts: “Represents value of common shares issued in connection with share exchange, valued at Cdn$0.18 per share; Cdn$1.1333=US$1.00”On a merger: “Acquisition of BriaCell Therapeutics Corp. by Ansell Capital Corp.”Signed by Matthew G. Wright, Chief Financial Officer. Newest notice filed Dec 12, 2014. Read the notice at the SEC .
equity, options SEC
What its filings and its own website say, sentence by sentence, each with its source.
BriaCell Therapeutics Corp. chose not to state its revenue in its newest notice of a funding round (Jun 2021).
SEC Form D · Jun 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2021
No products or services of BriaCell Therapeutics Corp. are on record.
No investor of BriaCell Therapeutics Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today Institutions holding Briacell Therapeutics Corp. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by BriaCell Therapeutics Corp. Name Role Named in Gadi Levin Executive officer Jun 2021 Jamieson Bondarenko Executive officer Jun 2021 William Williams Executive officer Jun 2021 Charles Wiseman Executive officer Dec 2014 Rahoul A. Sharan Executive officer Dec 2014 Jamieson Bondarenko Director Jun 2021 Martin Schmieg Director Jun 2021 Rebecca Taub Director Jun 2021 Vaughn Embro-Pantalony Director Jun 2021 William Williams Director Jun 2021 Charles Wiseman Director Dec 2014 Isaac A. Maresky Director Dec 2014 Rahoul A. Sharan Director Dec 2014 Saeid Babei Director Dec 2014
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.